2021 Fiscal Year Final Research Report

SDF-1 after preoperative CRT is associated with prognosis in advanced rectal cancer

Research Project

PDF

Project/Area Number	19K09071
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 55010:General surgery and pediatric surgery-related
Research Institution	The University of Tokushima
Principal Investigator	HIGASHIJIMA Jun 徳島大学, 大学院医歯薬学研究部(医学域), 徳島大学専門研究員 (30467815)
Co-Investigator(Kenkyū-buntansha)	柏原秀也徳島大学, 病院, 助教 (10548738) 池本哲也徳島大学, 病院, 特任教授 (20398019) 徳永卓哉徳島大学, 病院, 特任准教授 (30448328) 森根裕二徳島大学, 大学院医歯薬学研究部(医学域), 准教授 (60398021) 西正暁徳島大学, 病院, 助教 (70464344) 高須千絵徳島大学, 大学院医歯薬学研究部(医学域), 講師 (70582823) 吉川幸造徳島大学, 大学院医歯薬学研究部(医学域), 特任教授 (80448331)
Project Period (FY)	2019-04-01 – 2022-03-31
Keywords	直腸癌 / 放射線治療抵抗性 / 骨髄由来免疫制御細胞 / miR-223
Outline of Final Research Achievements	We clarified the significance of SDF-1 expression on chemoradiotherapy (CRT) resistance and prognosis in advanced lower rectal cancer patients. We evaluated 98 patients with advanced lower rectal cancer who underwent preoperative CRT. SDF-1 expression in surgical specimens was examined by immunohistochemistry. We divided the patients into SDF-1-positive- (n=52) and SDF-1-negative groups (n=46) and compared the clinicopathological factors and survival rates. The SDF-1-positive group was more resistant to CRT than the SDF-1-negative group. Overall survival (OS) in the SDF-1 positive group was significantly poorer vs. the SDF-1-negative group, and disease-free survival (DFS) was worse. Multivariate analysis confirmed that SDF-1 expression was a significant independent prognostic predictor of OS (p=0.04). SDF-1 expression after preoperative CRT is significantly associated with a poor prognosis in advanced lower rectal cancer patients and is a promising biomarker.
Free Research Field	下部消化管悪性腫瘍に対する低侵襲治療
Academic Significance and Societal Importance of the Research Achievements	化学放射線療法（CRT）は進行下部直腸癌患者に対し、局所腫瘍制御及び生存率向上、括約筋温存のための治療手段として広く用いられているが、直腸癌におけるSDF-1高発現は化学放射線抵抗性および術後再発と相関し、全生存期間の独立予後規定因子であり、今後進行下部直腸癌患者の治療抵抗性および予後不良のバイオマーカーとして期待される。